New Delhi: Avesthagen Ltd, a knowledge based Systems Biology Company, announced the start of Phase III human clinical trials for it’s recently launched brand of botanical bioActives.
Avesthagen and Manipal AcuNova have a strategic agreement for conducting Phase III human clinical studies for diabetes management for its branded bioActives Teestar™, Aspand™ and Cincata™.
These products have been developed by the bionutrition division of Avesthagen Limited from different medicinal plants selected from its proprietary database - ADePt™, and validated using MetaGrid™, its patented comprehensive constituent profiling technology.
Teestar™ acts by intervening with carbohydrate metabolism. The efficacy of Teestar™ was evaluated in pre-clinical studies wherein it showed significant reduction of blood glucose levels.
Aspand™ acts by inhibiting Dipeptidyl peptidase IV and by sensitising insulin. Aspand™ was tested on different cell lines in-house in different assays, where Aspand™ treated group showed inhibition of Dipeptidyl peptidase IV and better glucose homeostasis as compared to the control.
Cincata™ acts by inhibiting a-glucosidase and by acting synergistically with insulin, thereby increasing its potency. Cincata™ was tested on different cell lines in-house in different assays, where Cincata™ treated group showed inhibition of a-glucosidase, and better glucose homeostasis as compared to the control.
During pre-clinical studies all three bioActives recorded a significant decrease in blood sugar levels in diabetic animal models and also recorded a significant reduction in the level of glycated haemoglobin HbA1c in comparison to the controls.
Dr Villoo Morawala Patell, founder, chairperson and managing director of Avesthagen said, “We are pursuing aggressively Phase III clinical development of these bioActives to establish the parametres of the clinical trial design that can lead to regulatory approval.”